Transgene is a renowned biotech company specializing in immunotherapy and focused on developing therapeutic vaccines and oncolytic viruses to combat cancer. With a mission to push the boundaries of immunotherapy, Transgene combines cutting-edge technologies, a multidisciplinary team, and a prestigious international network. They offer two innovative therapeutic approaches.

One is myvac®, which is personalized immunotherapy that stimulates the patient's immune system to recognize and destroy tumors using their own genetic mutations. The other is Invir. IO®, a next-generation oncolytic virus platform that selectively attacks tumors.

Transgene's portfolio includes products like TG4050, TG4001, TG6002, TG6050, and BT-001, all of which have shown promising results in clinical trials. With its commitment to innovation and groundbreaking therapies, Transgene is at the forefront of revolutionizing cancer treatment